Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation

Table 4 Bivariate analysis of the relationship between categorical variables and troponin elevation

Variable	Troponin elevation		P value
	No	Yes
Gender
Male	918 (88.4%)	121 (11.6%)	0.78
Female	665 (88.8%)	84 (11.2%)
Race
Asia	96 (88.1%)	13 (11.9%)	0.38
Black	72 (88.9%)	9 (11.1%)
White	1030 (89.4%)	122 (10.6%)
Others	385 (86.3%)	61 (13.7%)
Expired
Yes	415 (77.7%)	119 (22.3%)	< 0.001
No	1168 (93.1%)	86 (6.9%)
Ventilator
Yes	334 (76.6%)	102 (23.4%)	< 0.001
No	1249 (92.4%)	103 (7.5%)
Intensive care unit
Yes	354 (77.0%)	106 (23.0%)	< 0.001
No	1229 (92.5%)	99 (7.5%)
Diabetes mellitus
Yes	314 (91.3%)	30 (8.7%)	0.08
No	1269 (87.9%)	175 (12.1%)
Hypertension
Yes	677 (89.6%)	79 (10.4%)	0.25
No	906 (87.8%)	126 (12.2%)
Chronic kidney disease
Yes	354 (82.9%)	73 (17.1%)	<0.001
No	1223 (90.3%)	132 (9.7%)
Congestive heart failure
Yes	279 (82.8%)	58 (17.2%)	< 0.001
No	1304 (89.9%)	147 (10.1%)
Chronic obstructive pulmonary disease
Yes	96 (87.3%)	14 (12.7%)	0.67
No	1487 (88.6%)	191 (11.4%)
Bradycardia
Yes	853 (88.4%)	112 (11.6%)	0.84
No	730 (88.7%)	93 (11.3%)
Use of Remdesivir
Yes	789 (89.4%)	94 (10.6%)	0.28
No	748 (87.7%)	94 (12.3%)
Use of dexamethasone
Yes	1069 (87.6%)	151 (12.4%)	0.08
No	514 (90.5%)	54 (9.5%)